CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
- Continuation of corporate transformation into commercial-ready biopharma company
- Management team strengthened with appointments of Chief Operating Officer Malte Greune and Chief Development Officer Klaus Edvardsen
- First-generation COVID-19 vaccine candidate, CVnCoV
- Final analysis reported of pivotal Phase 2b/3 study conducted in ten countries in variant-dominated environment
- Committed to seeking regulatory approval with EMA – submission of comprehensive clinical data packages within rolling submission ongoing
- Second-generation COVID-19 vaccine candidate, CV2CoV, jointly advanced with GSK
- Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone compared to first-generation backbone during challenge study and against range of variants, including Delta and Lambda variant
- Start of CV2CoV Phase 1 clinical trial anticipated in Q4 2021
- Oncology Programs
- Phase 1 trial extension of lead asset, CV8102, on track to fully recruit
- Legacy program, BI 1361849, developed in partnership with Boehringer Ingelheim, based on early protamine formulation terminated; companies assessing options for further collaboration
- Financials: Cash position of €1.36 billion as of June 30, 2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the second quarter and first half of 2021 and provided business update.